ZA200208163B - Pharmaceutical compositions comprising fluvastatin. - Google Patents

Pharmaceutical compositions comprising fluvastatin.

Info

Publication number
ZA200208163B
ZA200208163B ZA200208163A ZA200208163A ZA200208163B ZA 200208163 B ZA200208163 B ZA 200208163B ZA 200208163 A ZA200208163 A ZA 200208163A ZA 200208163 A ZA200208163 A ZA 200208163A ZA 200208163 B ZA200208163 B ZA 200208163B
Authority
ZA
South Africa
Prior art keywords
fluvastatin
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
ZA200208163A
Other languages
English (en)
Inventor
Oskar Kalb
Stephen Vallaza
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24192117&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200208163(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200208163B publication Critical patent/ZA200208163B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
ZA200208163A 2000-04-13 2002-10-10 Pharmaceutical compositions comprising fluvastatin. ZA200208163B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/549,222 US6242003B1 (en) 2000-04-13 2000-04-13 Organic compounds

Publications (1)

Publication Number Publication Date
ZA200208163B true ZA200208163B (en) 2003-08-26

Family

ID=24192117

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200208163A ZA200208163B (en) 2000-04-13 2002-10-10 Pharmaceutical compositions comprising fluvastatin.

Country Status (20)

Country Link
US (3) US6242003B1 (hu)
EP (2) EP2042163A1 (hu)
JP (2) JP2003530422A (hu)
KR (1) KR100510856B1 (hu)
CN (2) CN100457102C (hu)
AU (2) AU2001262196B8 (hu)
BR (1) BR0109943A (hu)
CA (1) CA2403591A1 (hu)
CZ (1) CZ20023379A3 (hu)
HU (1) HUP0300541A3 (hu)
IL (2) IL152077A0 (hu)
MX (1) MXPA02010136A (hu)
NO (1) NO20024891L (hu)
NZ (1) NZ521441A (hu)
PL (1) PL201268B1 (hu)
RU (1) RU2297223C2 (hu)
SG (1) SG160185A1 (hu)
SK (1) SK14622002A3 (hu)
WO (1) WO2001078680A2 (hu)
ZA (1) ZA200208163B (hu)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
CA2389616A1 (en) * 1999-11-03 2001-05-10 Howard J. Smith & Associates Pty Ltd. Liver selective therapy
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
PT1471887E (pt) 2002-02-04 2010-07-16 Elan Pharma Int Ltd ComposiãŽes de nanopartculas com lisozima como um estabilizador superficial
EP1336405A1 (en) * 2002-02-14 2003-08-20 Ranbaxy Laboratories, Ltd. Formulations of atorvastatin stabilized with alkali metal additions
JP4831965B2 (ja) * 2002-06-10 2011-12-07 エラン ファーマ インターナショナル，リミティド ＨＭＧ−ＣｏＡ還元酵素インヒビター誘導体（「スタチン」）を含むナノ粒子製剤、その新規組合せ、ならびにこれらの医薬組成物の製造
SI1515717T1 (sl) * 2002-06-13 2009-02-28 Novartis Ag Kalcijeve soli statinov, izvedenih iz indola
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
CA2519458A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
JP5546715B2 (ja) * 2003-03-17 2014-07-09 日本たばこ産業株式会社 Ｃｅｔｐ阻害剤の医薬組成物
US20040185093A1 (en) * 2003-03-18 2004-09-23 Szymczak Christopher E. Compositions containing sucralose
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
CA2465565A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050220875A1 (en) * 2004-03-31 2005-10-06 Agency For Science, Technology And Research Sustained-release tablet formulation
US20060062811A1 (en) * 2004-09-21 2006-03-23 Szymczak Christopher E Medicinal cooling emulsions
CA2589537A1 (en) * 2004-12-02 2006-06-08 Stephen Craig Dyar Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
PT1944029E (pt) * 2005-10-31 2012-02-09 Nissan Chemical Ind Ltd Preparação farmacêutica com excelente fotoestabilidade
CN101426478A (zh) * 2006-02-24 2009-05-06 特瓦制药工业有限公司 氟伐他汀钠药物组合物
EP1911441A3 (en) * 2006-10-11 2008-08-06 Lupin Limited Controlled release color stable pharmaceutical dosage form of HMG-COA reductase inhibitors, free of alkalizing or buffering agents
WO2008064259A2 (en) * 2006-11-21 2008-05-29 Biokey, Inc. Solid dispersion composition comprising fluvastatin
US20110052688A1 (en) * 2006-11-21 2011-03-03 San-Laung Chow Solid dispersion composition
CN101568340B (zh) * 2006-12-01 2011-06-15 日东电工株式会社 经皮吸收制剂
BRPI0719308A2 (pt) * 2006-12-01 2014-02-04 Nitto Denko Corp Método para supressão da coloração de preparação adesiva contendo donepzil e método para redução da quantidade de substâncias formadas relacionadas à donepezil.
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
WO2009145177A1 (ja) * 2008-05-30 2009-12-03 日東電工株式会社 ドネペジル含有貼付製剤およびその包装体
CN102046171B (zh) * 2008-05-30 2013-06-19 日东电工株式会社 经皮吸收制剂
CN102805739B (zh) * 2012-04-10 2013-08-14 宋芸 氟伐他汀钠缓释包衣滴丸及其制备方法
CN106344535B (zh) * 2016-08-29 2019-09-20 济南康和医药科技有限公司 一种氟伐他汀钠微孔渗透泵控释片及其制备方法
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US3852421A (en) 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
US3865935A (en) 1972-08-10 1975-02-11 Abbott Lab Tableting of erythromycin base
US3952096A (en) 1973-06-15 1976-04-20 Bristol-Myers Company Mixture of calcium carbonate and calcium-α-p-chlorophenoxyisobutyrate as an antihyperlipemic agent
US3891755A (en) 1973-07-11 1975-06-24 Abbott Lab Dosage formulation for erythromycin cetyl sulfate
US4357469A (en) 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
US4226849A (en) 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4259314A (en) 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4556678A (en) 1982-06-24 1985-12-03 Key Pharmaceuticals, Inc. Sustained release propranolol tablet
WO1984002131A1 (en) 1982-11-22 1984-06-07 Sandoz Ag Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
US4686237A (en) 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4744987A (en) 1985-03-08 1988-05-17 Fmc Corporation Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation
WO1987000044A1 (en) 1985-07-02 1987-01-15 The Upjohn Company Therapeutic formulations with bimodal release characteristics
DE3524572A1 (de) 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
US4734285A (en) * 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
JPH0776172B2 (ja) 1986-04-16 1995-08-16 藤沢薬品工業株式会社 マトリツクス錠
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB8624213D0 (en) 1986-10-09 1986-11-12 Sandoz Canada Inc Sustained release pharmaceutical compositions
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US4915954A (en) 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4929605A (en) 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US4997658A (en) 1988-11-21 1991-03-05 Merck & Co., Inc. Method for enhancing the lowering of plasma cholesterol levels
US5376383A (en) 1988-11-21 1994-12-27 Merck & Co., Inc. Method for enhancing the lowering of plasma-cholesterol levels
CA2007181C (en) 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US5126145A (en) 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
CA2016467A1 (en) 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
US5021053A (en) 1989-07-14 1991-06-04 Alza Corporation Oral osmotic device with hydrogel driving member
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
CA2045428A1 (en) 1990-06-26 1991-12-27 Alfred W. Alberts Method for enhancing the lowering of plasma cholesterol levels
US5147654A (en) 1990-07-23 1992-09-15 Alza Corporation Oral osmotic device for delivering nicotine
US5284662A (en) 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
DE69013689T2 (de) 1990-11-29 1995-03-02 Wei Ming Pharmaceutical Mfg Co Hilfsträger für direkte Verpressung.
HU221849B1 (hu) * 1991-12-12 2003-02-28 Novartis Ag. HMG-CoA reduktáz inhibitor fluvasztatint tartalmazó stabilizált gyógyszerkészítmények
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5543154A (en) 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US5393765A (en) 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US5419917A (en) 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US5582838A (en) 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
DE69625046T2 (de) 1995-12-22 2003-04-10 Kowa Co., Ltd. Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
WO1997049681A1 (en) 1996-06-24 1997-12-31 Astra Aktiebolag (Publ) Polymorphic compounds
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
SE9603667D0 (sv) 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions
SE9603668D0 (sv) 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
GB9703388D0 (en) * 1997-02-18 1997-04-09 Sandoz Yakuhin K K Tokyo Sykk Organic compounds
BE1011045A3 (fr) 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
EP1326604A2 (en) * 2000-04-12 2003-07-16 Novartis AG Combination of at least two compounds selected from an at1-receptorantagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20030171419A1 (en) 2003-09-11
AU2001262196B8 (en) 2005-12-01
AU2001262196B2 (en) 2005-08-11
IL152077A (en) 2009-02-11
BR0109943A (pt) 2003-05-27
NZ521441A (en) 2004-08-27
JP2003530422A (ja) 2003-10-14
PL201268B1 (pl) 2009-03-31
EP1272166A2 (en) 2003-01-08
WO2001078680A3 (en) 2002-04-11
HUP0300541A3 (en) 2009-04-28
NO20024891L (no) 2002-12-05
NO20024891D0 (no) 2002-10-10
CZ20023379A3 (cs) 2003-01-15
IL152077A0 (en) 2003-05-29
AU6219601A (en) 2001-10-30
CN1422151A (zh) 2003-06-04
US6432447B2 (en) 2002-08-13
CA2403591A1 (en) 2001-10-25
JP2007131647A (ja) 2007-05-31
RU2002129570A (ru) 2004-03-27
RU2297223C2 (ru) 2007-04-20
HUP0300541A2 (hu) 2003-07-28
SG160185A1 (en) 2010-04-29
CN1241545C (zh) 2006-02-15
MXPA02010136A (es) 2003-03-10
US6242003B1 (en) 2001-06-05
PL356904A1 (en) 2004-07-12
KR100510856B1 (ko) 2005-08-31
US20010043950A1 (en) 2001-11-22
SK14622002A3 (sk) 2003-04-01
WO2001078680A2 (en) 2001-10-25
KR20030019332A (ko) 2003-03-06
CN100457102C (zh) 2009-02-04
EP2042163A1 (en) 2009-04-01
CN1720912A (zh) 2006-01-18

Similar Documents

Publication Publication Date Title
ZA200208163B (en) Pharmaceutical compositions comprising fluvastatin.
ZA200003997B (en) Pharmaceutical compositions.
HUP0300582A3 (en) Pharmaceutical compositions
MXPA03000771A (es) Nuevas composiciones farmaceuticas.
GB0009584D0 (en) Pharmaceutical compositions
ZA200203486B (en) Novel pharmaceutical compositions.
ZA200210359B (en) Pharmaceutical compositions.
GB0020691D0 (en) Pharmaceutical combination
HUP0400553A3 (en) Pharmaceutical compositions
MXPA03002105A (es) Composiciones farmaceuticas.
GB0008485D0 (en) Pharmaceutical compositions
GB0012291D0 (en) Pharmaceutical combination
GB0009613D0 (en) Pharmaceutical compositions
GB0012293D0 (en) Pharmaceutical combination
GB0001337D0 (en) Pharmaceutical compositions
GB0003929D0 (en) Pharmaceutical compositions
GB0031282D0 (en) Pharmaceutical compositions
GB0008872D0 (en) Pharmaceutical compositions
GB0018321D0 (en) Pharmaceutical compositions
HU0700204D0 (en) Pharmaceutical compositions
GB0031288D0 (en) Pharmaceutical compositions
GB0000062D0 (en) Pharmaceutical compositions
ZA200303911B (en) Medicinal compositions.
GB0017666D0 (en) Pharmaceutical combination
GB0020769D0 (en) Pharmaceutical combination